HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Brian G. Barratt-Boyes Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, S. P. Articles by Raudkivi, P. J. Search for Related Content PubMed PubMed Citation Articles by Wong, S. P. Articles by Raudkivi, P. J.

Ann Thorac Surg 2000;69:1846-1850
© 2000 The Society of Thoracic Surgeons

---

Original articles: Cardiovascular

Early experience with the Mosaic bioprosthesis: a new generation porcine valve

^a Department of Cardiology, Green Lane Hospital, Auckland, New Zealand
^b Department of Cardiothoracic Surgery, Green Lane Hospital, Auckland, New Zealand

Address reprint requests to Dr Legget, Department of Cardiology, Green Lane Hospital, Green Lane West, Auckland 1005, New Zealand
e-mail: malcolml{at}ahsl.co.nz

Background. The Mosaic bioprosthesis is a new generation stented porcine valve.

Methods. Between May 1995 and April 1998, this valve was implanted in the aortic position in 98 patients (70 men; mean age, 69.2 years [34.2 to 83.6 years]). Preoperatively 35 patients were in New York Heart Association functional class 3 or 4. Fifty-nine patients underwent concomitant procedures. The mean duration at follow-up in January 1999 was 23.7 ± 10.2 months (0.3 to 39.4 months) and totaled 193 patient-years. All but one survivor was in New York Heart Association class 1 or 2.

Results. Early complications included 1 death, 3 reoperations for bleeding, greater than mild regurgitation (paravalvar) in 1 patient and thromboembolism in 4 patients. Late complications included four deaths, study-valve endocarditis in 3 patients, more than mild regurgitation or hemolysis in 2, and thromboembolism in 2 patients. Late follow-up echocardiography in all survivors showed a mean transaortic gradient of 13.6 ± 6.7 mm Hg, and an aortic valve area of 1.80 ± 0.61 cm². Valve replacement was followed by a significant and sustained decrease in left ventricular mass for all valve sizes. There has been no primary structural valve failure.

Conclusions. The early experience with the Mosaic valve in the aortic position has been promising.

This article has been cited by other articles:

				F.-C. Riess, R. Bader, E. Cramer, L. Hansen, B. Kleijnen, G. Wahl, J. Wallrath, S. Winkel, and N. Bleese Hemodynamic Performance of the Medtronic Mosaic Porcine Bioprosthesis Up to Ten Years Ann. Thorac. Surg., April 1, 2007; 83(4): 1310 - 1318. [Abstract] [Full Text] [PDF]

				W. B. Eichinger, F. Botzenhardt, R. Gunzinger, B. M. Kemkes, A. Sosnowski, D. Maiza, E. O. Coto, and N. Bleese European experience with the Mosaic bioprosthesis J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 333 - 339. [Abstract] [Full Text] [PDF]

				T. Aberg, X. Y. Jin, and P. Deverall Post operative assessment of a bioprosthetic aortic valve (Labcor) Eur. J. Cardiothorac. Surg., September 1, 2001; 20(3): 658 - 658. [Full Text] [PDF]

				D. J. Thomson, W.R. E. Jamieson, J. G. Dumesnil, J. J. Burgess, C. M. Peniston, J. Metras, J. A. Sullivan, J. C.W. Parrott, A. Maitland, and I. J. Cybulsky Medtronic mosaic porcine bioprosthesis: midterm investigational trial results Ann. Thorac. Surg., May 1, 2001; 71 (2007): S269 - S272. [Abstract] [Full Text] [PDF]